#Reyataz

Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.

Janssen’s single-tablet antiretroviral regimen was approved on July 17.

This connection remained even when researchers took into account various risk factors for cardiovascular disease.

Most of such drug resistance seen is to older drugs.

That’s compared with HIV-negative men.

A recent study compared birth outcomes among HIV-positive women exposed to various antiretroviral regimens.

Investigators behind the recent study that raised this concern suggest not combining the two until more research can be done.

A recent analysis of Europeans taking boosted protease inhibitors for HIV treatment found this pair prompted the best long-term response.

This marks the manufacturer’s fifth generic antiretroviral launch.

In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.

Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

The company is losing its exclusive rights to two HIV drugs: Reyataz and Sustiva.

This is according to a large study of U.S. veterans.

The two-drug regimen can cure the virus in as little as eight weeks.